In conclusion, the results presented here demonstrate that siNrf2-GCD treatment significantly increased the sensitivity to a pro-oxidant cytotoxic drug and reduced migration of CDDP-resistant bladder cancer cells. Here, GCDH is linked to urinary bladder carcinoma.